www.g4media.ro/rusia-va-utiliza-un-vaccin-autohton

Russia plans to use its internally developed cancer vaccine CaTeVac starting in 2027 for treating soft tissue sarcomas. Preclinical studies are complete, and documentation for production and clinical use is being prepared. The vaccine aims to train the immune system to recognize and destroy tumor cells. Future applications may include melanoma and other malignancies where standard treatments have failed. CaTeVac was developed by the N.N. Petrov National Medical Research Center of Oncology in St. Petersburg.